Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will…